Defiance Next Gen Altered Experience ETF (PSY) Stock Analysis

Defiance Next Gen Altered Experience ETF (PSY) Financial Services Profile

Defiance Next Gen Altered Experience ETF (PSY) provides exposure to the emerging legal medical psychedelics and cannabis industries by tracking companies involved in related activities. Utilizing a replication strategy, the fund mirrors the performance of its index, offering investors a focused approach to these evolving sectors within a non-diversified portfolio.

What Is the Investment Thesis for PSY?

The Defiance Next Gen Altered Experience ETF (PSY) presents a focused investment opportunity in the rapidly evolving legal medical psychedelics and cannabis industries. The fund's value is driven by the growth of these sectors, fueled by increasing acceptance of medical cannabis and emerging research into the therapeutic potential of psychedelics. A key catalyst is the ongoing regulatory changes and legalization efforts across various jurisdictions, which could significantly expand the market for these substances. However, the non-diversified nature of the fund and the inherent volatility of the cannabis and psychedelics industries pose potential risks. Investors should carefully consider the regulatory landscape, competitive pressures, and the evolving scientific understanding of these substances when evaluating PSY.

Based on FMP financials and quantitative analysis

PSY Key Highlights

PSY offers targeted exposure to the emerging legal medical psychedelics and cannabis industries.

• The fund employs a replication strategy, aiming to mirror the performance of its underlying index.
• PSY is a non-diversified ETF, concentrating its investments in a relatively small number of companies.
• The fund's performance is closely tied to the regulatory landscape and legalization efforts surrounding medical cannabis and psychedelics.
• As of 2026-03-18, PSY has a market capitalization of $4.65M and does not offer a dividend yield.

Who Are PSY's Competitors?

PSY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PSY's Key Strengths?

Targeted exposure to high-growth potential sectors.

• Replication strategy ensures alignment with the underlying index.
• First-mover advantage in the medical psychedelics ETF space.
• Provides diversification within the cannabis and psychedelics industries.

What Are PSY's Weaknesses?

Non-diversified nature increases volatility.

• Concentration in a niche market may limit growth potential.
• Performance is highly dependent on regulatory changes.
• Small market capitalization may impact liquidity.

What Could Drive PSY Stock Higher?

Regulatory approvals for medical cannabis and psychedelics in key markets.

• Increasing research and clinical trials demonstrating the efficacy of psychedelics.
• Growing public awareness and acceptance of medical cannabis and psychedelics.
• New product launches and innovations in the cannabis and psychedelics industries.

What Are the Key Risks for PSY?

Regulatory uncertainty and potential policy reversals.

• Negative public perception and social stigma.
• Competition from established pharmaceutical companies.
• Market volatility and economic downturns.
• Dependence on a limited number of companies within the index.

What Are the Growth Opportunities for PSY?

• Expansion of Legalization: The ongoing trend of legalization of medical cannabis and psychedelics in various jurisdictions represents a significant growth opportunity for PSY. As more countries and states legalize these substances, the market for companies involved in their production, distribution, and research will expand, driving demand for PSY. The timeline for this growth is dependent on the pace of regulatory changes, but the trend is expected to continue in the coming years. This expansion could lead to a substantial increase in the fund's assets under management.
• Increasing Acceptance of Medical Cannabis: The growing acceptance of medical cannabis as a treatment option for various conditions is driving demand for products and services in this sector. This trend is expected to continue as more research supports the efficacy of medical cannabis and as more healthcare providers become comfortable prescribing it. PSY is well-positioned to benefit from this trend, as it provides exposure to companies involved in the medical cannabis industry.
• Emerging Research into Psychedelics: The increasing research into the therapeutic potential of psychedelics is creating new opportunities for companies involved in this sector. Studies have shown that psychedelics may be effective in treating conditions such as depression, anxiety, and PTSD. As more research is conducted and as regulatory barriers are lowered, the market for psychedelic-based therapies is expected to grow significantly. PSY provides exposure to companies involved in the research and development of psychedelic-based therapies.
• Development of New Products and Services: Companies in the medical cannabis and psychedelics industries are constantly developing new products and services to meet the evolving needs of patients and consumers. This innovation is driving growth in these sectors and creating new opportunities for investment. PSY is well-positioned to benefit from this trend, as it provides exposure to a diverse range of companies involved in the development of new products and services. These include novel delivery methods, personalized therapies, and innovative formulations.
• Increased Investment in Research and Development: As the medical cannabis and psychedelics industries mature, there is increasing investment in research and development. This investment is driving innovation and leading to the development of new therapies and products. PSY benefits from this trend by holding companies that are at the forefront of research and development in these fields. This includes companies conducting clinical trials, developing new formulations, and exploring new applications for medical cannabis and psychedelics.

What Threats Does PSY Face?

• Regulatory setbacks or changes in government policies.
• Increased competition from new entrants in the ETF space.
• Negative public perception of cannabis and psychedelics.
• Market volatility and economic downturns.

What Are PSY's Competitive Advantages?

• First-mover advantage in offering a dedicated ETF focused on the next-gen altered experience market.
• Replication strategy provides transparency and predictability in investment holdings.
• Access to a diversified portfolio of companies within the emerging medical psychedelics and cannabis sectors.

What Does PSY Do?

The Defiance Next Gen Altered Experience ETF (PSY) is designed to provide investors with exposure to companies operating within the burgeoning legal medical psychedelics, medical cannabis, cannabis pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine industries. This ETF operates by tracking a rules-based index that identifies and includes companies actively engaged in legal activities related to these substances, adhering to the national laws of their respective countries. The fund's investment strategy centers around replicating the composition of its underlying index. This means that PSY invests in all the component securities of the index, maintaining approximate proportions to mirror the index's weighting. By employing this replication strategy, the ETF aims to closely match the performance of the index, providing investors with a return profile that reflects the overall performance of the targeted sectors. It is important to note that PSY is a non-diversified fund. This means that it concentrates its investments in a relatively small number of companies within the specified industries, which can lead to higher volatility compared to more diversified ETFs. The fund's focus on niche sectors like medical psychedelics and cannabis positions it as a specialized investment vehicle for those seeking targeted exposure to these emerging markets.

What Products and Services Does PSY Offer?

• Tracks the performance of companies involved in legal medical psychedelics activities.
• Tracks the performance of companies involved in legal medical cannabis activities.
• Tracks the performance of companies involved in cannabis pharmaceuticals activities.
• Tracks the performance of companies involved in cannabidiol (CBD) derivatives activities.
• Tracks the performance of companies involved in ketamine activities.
• Invests in companies operating under the national laws of their respective countries.
• Employs a replication strategy to mirror the composition of its underlying index.

How Does PSY Make Money?

• Tracks a rules-based index of companies involved in the legal medical psychedelics and cannabis industries.
• Invests in the component securities of the index in the same approximate proportions.
• Generates returns based on the performance of the underlying companies in the index.

What Industry Does PSY Operate In?

The Defiance Next Gen Altered Experience ETF (PSY) operates within the asset management industry, specifically targeting the emerging markets of legal medical psychedelics and cannabis. These sectors are experiencing rapid growth, driven by increasing acceptance of medical cannabis and ongoing research into the therapeutic potential of psychedelics. The competitive landscape includes other ETFs and investment vehicles focused on cannabis, such as BAL, BIGB, DDG, DMRM and FEEM, but PSY differentiates itself by including exposure to the medical psychedelics industry. The overall market size for cannabis and psychedelics is projected to grow significantly in the coming years, driven by regulatory changes and increasing consumer demand.

Who Are PSY's Key Customers?

• Retail investors seeking exposure to the medical psychedelics and cannabis industries.
• Institutional investors looking to diversify their portfolios with alternative investments.
• Investors interested in the potential growth of the emerging legal cannabis and psychedelics markets.

How Defiance Next Gen Altered Experience ETF Is Valued

Defiance Next Gen Altered Experience ETF carries a market capitalization of $4.65M, placing it in the micro-cap category.

Return on equity for Defiance Next Gen Altered Experience ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. PSY trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

The most recent 12 insider filings for Defiance Next Gen Altered Experience ETF break down as 11 sales and 1 purchases. On net that is roughly 41K shares disposed (about $26K), a signal worth weighing alongside the fundamentals.

PSY Financials

PSY Latest News

No recent news available for PSY.

PSY Analyst Consensus

PSY MoonshotScore

Common Questions About PSY (Financial Services)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources